The importance of nonpharmacogenetic factors in endocrine therapy

Pharmacogenomics

Volumn 13, Issue 6, 2012, Pages 721-728

  McCowan, Colin ^a   Thompson, Alastair M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

adherence; aromatase inhibitors; breast cancer; persistence; tamoxifen

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; TAMOXIFEN; VITAMIN D;

ARTHRALGIA; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CARCINOMA; DRUG EFFICACY; DRUG ERUPTION; ENDOMETRIAL DISEASE; ENDOMETRIAL THICKENING; EXERCISE; FRACTURE; GASTROINTESTINAL DISEASE; HORMONAL THERAPY; HOT FLUSH; HUMAN; LONG TERM CARE; OSTEOPENIA; OSTEOPOROSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; REVIEW; RISK FACTOR; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; MEDICATION ADHERENCE; NEOPLASMS, HORMONE-DEPENDENT; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84859996304     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.29     Document Type: Review

References (101)

1. Cuzick J, Sestak I, Baum M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11(12), 1135-1141 (2010).
2. van de Velde CJH, Rea D, Seynaeve C et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised Phase 3 trial. Lancet 377(9762), 321-331 (2011).
3. Early Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793), 771-784 (2011).
4. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J. Clin. 59(1), 56-66 (2009).
5. Last J. A Dictionary of Epidemiology (4th Edition). Last J (Ed.). Oxford University Press, Inc., NY, USA (2001).
6. Osterberg L, Blaschke T. Adherence to medication. N. Engl. J. Med. 353(5), 487-497 (2005). (Pubitemid 41127293)
7. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 71(1-2), 1-9 (2006).
8. Dewar JA, Stewart HJ, MacDonald TM. Tamoxifen compliance in a clinical trial. Breast 5(3), 152-153 (1996). (Pubitemid 26234103)
9. Fisher B, Costantino JP, Redmond CK et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst. 86(7), 527-537 (1994). (Pubitemid 24111008)
10. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl Cancer Inst. 88(21), 1529-1542 (1996). (Pubitemid 26374506)
11. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J. Clin. Oncol. 19(2), 322-328 (2001). (Pubitemid 32112842)
12. Murthy V, Bharia G, Sarin R, Murthy V, Bharia G, Sarin R. Tamoxifen non-compliance: does it matter? Lancet Oncol. 3(11), 654 (2002). (Pubitemid 35314907)
13. Patridge A, Wang P, Winer E, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J. Clin. Oncol. 21(4), 602-606 (2003). (Pubitemid 46621892)
14. Ziller V, Kalder M, Albert US et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann. Oncol. 20(3), 431-436 (2009).
15. Partridge AH, Lafountain A, Mayer E et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J. Clin. Oncol. 26(4), 556-562 (2008). (Pubitemid 351264348)
16. Hershman DL, Kushi LH, Shao T et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J. Clin. Oncol. 28(27), 4120-4128 (2010).
17. McCowan C, Shearer J, Donnan PT et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br. J. Cancer 99(11), 1763-1768 (2008).
18. Dezentje VO, Van Blijderveen NJC, Gelderblom H et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J. Clin. Oncol. 28(14), 2423-2429 (2010).
19. Thompson A, Johnson A, Quinlan P et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res. Treat. 125(1), 279-287 (2010).
20. Hershman D, Shao T, Kushi L et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res. Treat. 126(2), 529-537 (2011).
21. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit. Rev. Oncol. Hematol. 73(2), 156-166 (2010).
22. Habashy HO, Powe DG, Staka CM et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res. Treat. 119(2), 283-293 (2010).
23. Rae JM, Sikora MJ, Henry NL et al. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J. 9(4), 258-264 (2009).
24. Maurice A, Howell A, Evans DG et al. Predicting compliance in a breast cancer prevention trial. Breast J. 12(5), 446-450 (2006). (Pubitemid 44337438)
25. Kok M, Zwart W, Holm C et al. PKA-induced phosphorylation of EPa at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res. Treat. 125(1), 1-12 (2011).
26. Aapro MS. Challenges in clinical patient management. Cancer Invest. 28(Suppl. 1), 14-27 (2010).
27. Guth U, Huang DJ, Schotzau A et al. Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br. J. Cancer 99(3), 428-433 (2008).
28. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J. Natl Cancer Inst. 88, 1543-1549 (1996).
29. Bramwell VH, Pritchard KI, Tu D et al. A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada-Clinical Trials Group Trial, MA.12). Ann. Oncol. 21(2), 283-290 (2010).
30. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J. Clin. Oncol. 22(16), 3309-3315 (2004). (Pubitemid 41103687)
31. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen. Cancer 109(5), 832-839 (2007).
32. Owusu C, Buist DS, Field TS et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J. Clin. Oncol. 26(4), 549-555 (2008). (Pubitemid 351264347)
33. Van Herk-Sukel M, Van De Poll-Franse L, Voogd A, Nieuwenhuijzen G, Coebergh J, Herings R. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res. Treat. 122(3), 843-851 (2010).
34. Ma AMT, Barone J, Wallis AE et al. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am. J. Surg. 196(4), 500-504 (2008).
35. Narod SA. Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation. J. Clin. Oncol. 28(33), e698-e699 (2010).
36. Yood MU, Owusu C, Buist DS et al. Mortality impact of less-than-standard therapy in older breast cancer patients. J. Am. Coll. Surg. 206(1), 66-75 (2008). (Pubitemid 350267255)
37. Fjsne HE, Jacobsen AB, Lundgren S; Norwegian Breast Cancer Group (NBCG). Adjuvant cyclic tamoxifen and megestrol acetate treatment in postmenopausal breast cancer patients-longterm follow-up. Eur. J. Surg. Oncol. 34(1), 6-12 (2008). (Pubitemid 350296766)
38. Boehm DU, Lebrecht A, Eckhardt T et al. Quality of life and adjuvant tamoxifen treatment in breast cancer patients. Eur. J. Cancer Care 18(5), 500-506 (2009).
39. Garreau JR, Delamelena T, Walts D et al. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am. J. Surg. 192(4), 496-498 (2006). (Pubitemid 44362983)
40. Perez EA. Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Res. Treat. 105(Suppl. 1), 75-89 (2007). (Pubitemid 47524804)
41. Hadji P. Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr. Rel. Cancer 15(1), 73-90 (2008). (Pubitemid 351449729)
42. Jones SE, Cantrell J, Vukelja S et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a tamoxifen exemestane adjuvant multicenter trial substudy. J. Clin. Oncol. 25(30), 4765-4771 (2007). (Pubitemid 350086479)
43. Crivellari D, Sun Z, Coates AS et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J. Clin. Oncol. 26(12), 1972-1979 (2008).
44. Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Re. Anticancer Ther. 9(1), 51-60 (2009).
45. Rosell J, Nordenskjold B, Bengtsson NO et al. Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial. Br. J. Cancer 104(6), 899-902 (2011).
46. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J. Natl Cancer Inst. 103(17), 1299-1309 (2011).
47. Hernandez RK, Sorensen HT, Pedersen L et al. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 115(19), 4442-4449 (2009).
48. Onitilo AA, Mccarty CA, Wilke RA et al. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res. Treat. 115(3), 643-650 (2009).
49. Cortesi L, De Matteis E, Rashid I et al. Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based study. Int. J. Gynecol. Cancer 19(8), 1358-1363 (2009).
50. Coleman RE, Bolten WW, Lansdown M et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat. Rev. 34(3), 275-282 (2008).
51. Henry NL, Giles JT, Stearns V, Henry NL, Giles JT, Stearns V. Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. Oncology (Williston Park) 22(12), 1401-1408 (2008).
52. Cella D, Fallowfield LJ, Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res. Treat. 107(2), 167-180 (2008). (Pubitemid 350265697)
53. Hong S, Didwania A, Olopade O et al. The expanding use of third-generation aromatase inhibitors: what the general internist needs to know. J. Gen. Int. Med. 24(Suppl. 2), S383-S388 (2009).
54. Prieto-Alhambra D, Javaid M, Servitja S et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res. Treat. 125(3), 869-878 (2011).
55. Puhalla S, Jankowitz RC, Davidson NE. Adjuvant endocrine therapy for breast cancer: don't ditch the switch! J. Natl Cancer Inst. 103(17), 1280-1282 (2011).
56. Litsas G. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence. Oncol. Nurs. Forum 35(4), 714-721 (2008).
57. Snoj N, Paridaens R, Cufer T, Snoj N, Paridaens R, Cufer T. Current controversies in extended adjuvant endocrine therapy for early breast cancer. Curr. Opin. Oncol. 20(6), 627-633 (2008).
58. Mortimer JE. Managing the toxicities of the aromatase inhibitors. Curr. Opin. Obstet. Gynecol. 22(1), 56-60 (2010).
59. Wengstrom Y. Effectively nursing patients receiving aromatase inhibitor therapy. Breast 17(3), 227-238 (2008).
60. Bourque F, Karama S, Looper K et al. Acute tamoxifen-induced depression and its prevention with venlafaxine. Psychosomatics 50(2), 162-165 (2009).
61. Kesim MD, Aydin Y, Atis A, Mandiraci G. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric 11(3), 252-257 (2008).
62. Winters L, Habin K, Flanagan J, Cashavelly BJ. 'I feel like I am 100 years old!' Managing arthralgias from aromatase inhibitors. Clin. J. Oncol. Nurs. 14(3), 379-382 (2010).
63. Park H, Parker GL, Boardman CH, Morris MM, Smith TJ. A pilot Phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Support Care Cancer 19(6), 859-863 (2011).
64. Hackshaw A, Roughton M, Forsyth S et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J. Clin. Oncol. 29(13), 1657-1663 (2011).
65. Rozenberg S, Antoine C, Carly B et al. Improving quality of life after breast cancer: prevention of other diseases. Menopause Int. 13(2), 71-74 (2007).
66. Macleod U, Ross S, Twelves C, George WD, Gillis C, Watt GC. Primary and secondary care management of women with early breast cancer from affluent and deprived areas: retrospective review of hospital and general practice records. BMJ 320(7247), 1442-1445 (2000). (Pubitemid 30311675)
67. Ogle KS, Swanson GM, Woods N, Azzouz F. Cancer and comorbidity: redefining chronic diseases. Cancer 88(3), 653-663 (2000). (Pubitemid 30056943)
68. Houterman S, Janssen-Heijnen ML, Verheij CD et al. Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Br. J. Cancer 90(12), 2332-2337 (2004). (Pubitemid 38961896)
69. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291(20), 2441-2447 (2004). (Pubitemid 38669187)
70. Fleming ST, Pursley HG, Newman B et al. Comorbidity as a predictor of stage of illness for patients with breast cancer. Med. Care 43(2), 132-140 (2005). (Pubitemid 40222631)
71. Louwman WJ, Janssen-Heijnen ML, Houterman S et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur. J. Cancer 41(5), 779-785 (2005). (Pubitemid 40347298)
72. Aapro M, Monfardini S, Jirillo A et al. Management of primary and advanced breast cancer in older unfit patients (medical treatment). Cancer Treat. Rev. 35(6), 503-508 (2009).
73. Brauch H, Jordan VC, Brauch H, Jordan VC. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? Eur. J. Cancer 45(13), 2274-2283 (2009).
74. Colleoni M, Giobbie-Hurder A. Benefits and adverse effects of endocrine therapy. Ann. Oncol. 21(Suppl. 7), vii107-vii111 (2010).
75. Macleod U, Ross S, Gillis C, Mcconnachie A, Twelves C, Watt GCM. Socio-economic deprivation and stage of disease at presentation in women with breast cancer. Ann. Oncol. 11(1), 105-107 (2000). (Pubitemid 30084589)
76. Thomson CS, Hole DJ, Twelves CJ, Brewster DH, Black RJ. Prognostic factors in women with breast cancer: distribution by socioeconomic status and effect on differences in survival. J. Epidemiol. Community Health 55(5), 308-315 (2001). (Pubitemid 32336969)
77. Macleod U, Ross S, Twelves C, George WD, Gillis C, Watt GCM. Primary and secondary care management of women with early breast cancer from affluent and deprived areas: retrospective review of hospital and general practice records. BMJ 320(7247), 1442-1445 (2000). (Pubitemid 30311675)
78. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J. Natl Cancer Inst. 94(7), 490-496 (2002). (Pubitemid 34411287)
79. Henley NC, Hole DJ, Kesson E, Burns HJG, George WD, Cooke TG. Does deprivation affect breast cancer management? Br. J. Cancer 92(4), 631-633 (2005). (Pubitemid 40460595)
80. Baker L, Quinlan PR, Patten N et al. p53 mutation, deprivation and poor prognosis in primary breast cancer. Br. J. Cancer 102(4), 719-726 (2010).
81. Munro AJ, Bentley AHM. Deprivation, comorbidity and survival in a cohort of patients with colorectal cancer. Eur. J. Cancer Care 13(3), 254-262 (2004). (Pubitemid 38834457)
82. Munro AJ. Keynote comment: deprivation and survival in patients with cancer: we know so much, but do so little. Lancet Oncol. 6(12), 912-913 (2005). (Pubitemid 41685205)
83. Kelly CM, Juurlink DN, Gomes T et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340, c693 (2010).
84. Cronin-Fenton D, Lash TL, Sorensen HT. Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality. Future Oncol. 6(6), 877-880 (2010).
85. Lash TL, Cronin-Fenton D, Ahern TP et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol. 49(3), 305-312 (2010).
86. Pritchard K. Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer? Breast Cancer Res. 12(Suppl. 4), S18 (2010).
87. Ferraldeschi R, Howell SJ, Thompson AM, Newman WG. Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen. J. Clin. Oncol. 28(29), e584-e585 (2010).
88. Sideras K, Ingle JN, Ames MM et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. J. Clin. Oncol. 28(16), 2768-2776 (2010).
89. Lash TL, Cronin-Fenton D, Ahern TP et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J. Natl Cancer Inst. 103(6), 489-500 (2011).
90. Higgins MJ, Stearns V. Pharmacogenetics of endocrine therapy for breast cancer. Ann. Rev. Med. 62(1), 281-293 (2011).
91. Filipits M, Rudas M, Heinzl H et al. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Clin. Cancer Res. 15(18), 5888-5894 (2009).
92. Lehn S, Ferno M, Jirstrom K, Ryden L, Landberg G. A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle 10(6), 956-962 (2011).
93. Ruiter R, Bijl MJ, Van Schaik RH et al. CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics 11(10), 1367-1375 (2011).
94. Morgan DA, Refalo NA, Cheung KL. Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy. Breast 20(3), 215-219 (2011).
95. Elwyn G, Edwards A, Britten N. 'Doing prescribing': how doctors can be more effective. BMJ 327(7419), 864-867 (2003). (Pubitemid 37271707)
96. Stewart DE, Cheung AM, Duff S et al. Attributions of cause and recurrence in long-term breast cancer survivors. Psychooncology 10(2), 179-183 (2001).
97. Pellegrini I, Sarradon-Eck A, Soussan PB et al. Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view. Psychooncology 19(5), 472-479 (2010).
98. Kerr J, Engel J, Schlesinger-Raab A, Sauer H, Hölzel D. Communication, quality of life and age: results of a 5-year prospective study in breast cancer patients. Ann. Oncol. 14(3), 421-427 (2003). (Pubitemid 36367420)
99. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA 288(22), 2868-2879 (2002). (Pubitemid 35425073)
100. Fontein DBY, Nortier JWR, Liefers GJ et al. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial. Eur. J. Surg. Oncol. 38(2), 110-117 (2012).
101. Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A, Brodie AMH. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res. 68(12), 4518-4524 (2008).